Axsome and Marinus go opposite ways on SAGE-217 miss

Marinus Pharmaceuticals (NASDAQ:MRNS) is up 3% premarket while Axsome Therapeutics (NASDAQ:AXSM) is down 8% following Sage Therapeutics’ failed Phase 3 study of SAGE-217 in major depressive disorder (MDD).

SAGE is down 62% premarket.

SAGE-217 is a next-generation GABA modulator, specifically, a neuroactive steroid.

Marinus is developing ganaxolone, also a GABA modulator, for postpartum depression.

Axsome is developing AXS-05, an NMDA receptor agonist, for MDD.

https://seekingalpha.com/news/3524001-axsome-and-marinus-go-opposite-ways-on-sageminus-217-miss